Back to results
US 2009/0275618 A1Published application
1, 5-diphenyl-3-benzylamino-1, 5-dihydropyrrolidin-2-one as cb1 receptor modulators
AssigneeEli Lilly and Company
InventorsDavid Scott Coffey, Jingdan Hu, Stacy Jo Keding, Joseph Herman Krushinski, JR., John Mehnert Schaus, David Edward Tupper
Life of this patent
Estimating the term…
Abstract
Compounds and pharmaceutical compositions of Formula (I) by blockade of the CB1 receptors via an inverse agonism mechanism which are useful for reducing body weight in mammals, cognitive impairment associated with schizophrenia, mitigating treatment emergent weight gain observed during treatment with antipsychotics and have increased bioavailability.
Claims26
A compound of Formula
- wherein:
- R1 is selected from the group consisting of:
- a) —H,
- b) halo,
- c) —OCF3,
- d) —OCH3,
- e) methyl,
- f)—SO2CH3,
- g) —CF3, and
- h)—CN;
- R2 is at least one substituent independently selected from the group consisting of:
- a) —H,
- b) halo,
- c) —CF3,
- d) —(C1-C4) alkyl,
- e) cyclopropyl,
- f) —O-cyclopropyl,
- g) —SCF3,
- h) —OCF3
- i) —OCH2CF3,
- j) —CN, and
- k) —O—(C1-C3)alkyl;
- R3 is at least one substituent independently selected from selected from the group consisting of:
- a) —H,
- b) —CF3,
- c) —(C1-C4) alkyl,
- d) cyclopropyl,
- e) —OCH3,
- f) halo, and
- g) phenyl;
- each R4 and R5 is independently selected from the group consisting of H, methyl, and ethyl, or both R4 and R5 may be taken together with the carbon to which each is attached to form a cyclopropyl ring;
- or a pharmaceutically acceptable salt thereof.
29 more elements
A compound of Formula
-14. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.